# US 2010/0297159 A1 · Thomsen-friedenreich disaccharide modified immunogen (tfd), preparation procedure, compositions comprising it, uses, and treatment methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0297159 A1
- Document ID: US20100297159A1
- Status: Published application
- Kind: A1
- Application number: 12/743,956
- Filed: 2008-11-19
- Published: 2010-11-25
- Earliest claimed: 2007-11-20
- Assignees: Consejo Nacional De Investigaciones Cietificas Y Tecnicas (Conicet); Universidad Nacional De Cordoba; Inis Biotec LLC
- Inventors: Fernando José Irazoqui; Víctor Germán Sendra; Gustavo Alejandro Nores
- Web page: https://patentgrep.com/patent/US20100297159A1

## CPC

- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- A61K 39/001169: {Tumor associated carbohydrates}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/04: Immunostimulants
- A61K 2039/6062: {Muramyl peptides}
- A61K 2039/6081: {Albumin; Keyhole limpet haemocyanin [KLH]}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Modified Thomsen-Friedenreich disaccharide (TFD) immunogen, preparation procedure, compositions containing it, uses, and treatment methods. More specifically, the present invention refers to a immunogen obtained by modifying TFD, and comprising the general formula D-TFD-Lys(n)-C, wherein D is a hydrophobic terminal residue, TFD is disaccharide Galβ3GalNAcα; Lys(n) is a lysine connector, and n is an integer between 1 and 5, and C is a carrier. In a preferred embodiment, the modified invention immunogen comprises the general formula BzlαTFD-Lys5-KLHs, wherein Bzl is benzyl, TFD is disaccharide Galβ3GalNAcα; Lys5 is penta-lysine, and KLHs is succinilated Keyhole limpets hemocyanin.

## Claims

### Claim 1

A modified Thomsen-Friedenreich disaccharide (TFD) immunogen, characterized by comprising general formula D-TFD-Lys(n)-C, wherein
D is a hydrophobic terminal residue,
TFD is disaccharide Galβ3GalNAcα;
Lys(n) is a lysine connector and n is an integer between 1 and 5, and
C is a carrier.

### Claim 2 (depends on 1)

The immunogen of claim 1, characterized in that the hydrophobic terminal residue is selected from the group consisting of benzyl, p-nitrophenyl, butyl, propyl, ethyl, and methyl.

### Claim 3 (depends on 2)

The immunogen of claim 2, characterized in that the hydrophobic terminal residue is benzyl.

### Claim 4 (depends on 1)

The immunogen of claim 1, characterized in that the hydrophobic terminal residue is covalently linked to TFD GalNAc C1 in α position.

### Claim 5 (depends on 1)

The immunogen of claim 1, characterized in that the lysine connector is a penta-lysine.

### Claim 6 (depends on 1)

The immunogen of claim 1, characterized in that the carrier is selected from the group consisting of Keyhole limpets hemocyanin (KLH), and muramyl-dipeptide (MDP).

### Claim 7 (depends on 6)

The immunogen of claim 6, characterized in that the carrier is Keyhole limpets hemocyanin.

### Claim 8 (depends on 6)

The immunogen of claim 6, characterized in that the carrier is succinikated Keyhole limpets hemocyanin (KLHs).

### Claim 9 (depends on 1)

The immunogen of claim 1, characterized by being BzlαTFD-Lys5-KLHs, wherein Bzl is benzyl, TFD is disaccharide Galβ3GalNAcα; Lys5 is a penta-lysine, and KLHs is succinilated Keyhole limpets hemocyanin.

### Claim 10 (depends on 1)

A procedure for preparing immunogen of claim 1, characterized by comprising the following stages,
a. covalently link lysine connector Lys(n) to a carrier, wherein n is an integer between 1 and 5;
b. oxydize molecule BzlαTFD in terminal galactose carbon 6 to generate an aldehyde on said C6;
c. covalently link amine residue of connector Lys(n)-C from stage a) and aldehyde in terminal galactose C6 of BzIaTFD from stage de la b) by reduction amination in the presence of NaCNBH3; y
d) dialyze the reaction product and recovery the immunogen.

### Claim 11 (depends on 10)

The procedure of claim 10, characterized in that carrier C is selected from the group consisting of KLHs and muramyl-dipeptide (MDP).

### Claim 12 (depends on 10)

The procedure of claim 10, characterized in that the carrier is KLHs and it links covalently to connector Lys(n) in the presence of 1-ethyl-3-(3-dimetilaminopropil) carbodiimida (EDC).

### Claim 13 (depends on 10)

The procedure of claim 10, characterized in that the oxydation stage b) is carried out in the presence of the enzyme galactose oxydase.

### Claim 14

A composition to increase anti-tumoral immunity, characterized by comprising an effective amount of a modified Thomsen-Friedenreich disaccharide (TDF) immunogen of formula D-TFD-Lys(n)-C, wherein D is a hydrophobic terminal residue, TFD is disaccharide Galβ3GalNAcα, Lys(n) is a lysine connector, and n is an integer between 1 and 5, and C is a carrier; and pharmaceutically acceptable supports and/or excipients.

### Claim 15 (depends on 14)

The composition of claim 14, characterized in that the hydrophobic terminal residue is selected from the group consisting of benzyl, p-nitrophenyl, butyl, propyl, ethyl, and methyl.

### Claim 16 (depends on 15)

The composition of claim 15, characterized in that the hydrophobic terminal residue is benzyl.

### Claim 17 (depends on 14)

The composition of claim 14, characterized in that the hydrophobic terminal residue is covalently linked to TFD GalNAc C1 in position α.

### Claim 18 (depends on 14)

The composition of claim 14, characterized in that the lysine connector is a penta-lysine.

### Claim 19 (depends on 14)

The composition of claim 14, characterized in that the carrier is selected from the group consisting of Keyhole limpets hemocyanin (KLH), and muramyl-dipeptide (MDP).

### Claim 20 (depends on 19)

The composition of claim 19, characterized in that the carrier is Keyhole limpets hemocyanin.

### Claim 21 (depends on 19)

The composition of claim 19, characterized in that the carrier is succinilated Keyhole limpets hemocyanin.

### Claim 22 (depends on 14)

The composition of claim 14, characterized in that the immunogen is BzlαTFD-Lys5-KLHs, wherein Bzl is benzyl, TFD is disaccharide Galβ3GalNAcα; Lys5 is a penta-lysine, and KLHs is succinilated Keyhole limpets hemocyanin.

### Claim 23 (depends on 14)

The composition of claim 14, characterized by being in the form selected from the group consisting of liquid, solid, gels, and aerosol forms.

### Claim 24 (depends on 14)

The composition of claim 14, characterized by also comprising an adjuvant.

### Claim 25

A composition to inhibit adhesion of tumor cells and metastatic ability, characterized by comprising an effective amount of a modified Thomsen-Friedenreich disaccharide (TDF) of general formula D-TFD-Lys(n)-C, wherein D is a hydrophobic terminal residue, TFD is disaccharide Galβ3GalNAcα, Lys(n) is a lysine connector, and n is an integer between 1 and 5, and C is a carrier; and pharmaceutically acceptable supports and/or excipients.

### Claim 26 (depends on 25)

The composition of claim 25, characterized in that the hydrophobic terminal residue is selected from the group consisting of benzyl, p-nitrofenilo, butyl, propyl, ethyl, and methyl.

### Claim 27 (depends on 26)

The composition of claim 26, characterized in that the hydrophobic terminal residue is benzyl.

### Claim 28 (depends on 25)

The composition of claim 25, characterized in that the hydrophobic terminal residue is covalently linked to TFD GalNAc C1 in position α.

### Claim 29 (depends on 25)

The composition of claim 25, characterized in that the lysine connector is a penta-lysine.

### Claim 30 (depends on 25)

The composition of claim 25, characterized in that the carrier is selected from the group consisting of Keyhole limpets hemocyanin (KLH), and muramyl dipeptide (MDP).

### Claim 31 (depends on 30)

The composition of claim 30, characterized in that the carrier is Keyhole limpets hemocyanin.

### Claim 32 (depends on 30)

The composition of claim 30, characterized in that the carrier is succinilated Keyhole limpets hemocyanin.

### Claim 33 (depends on 25)

The composition of claim 25, characterized in that immunogen is BzlαTFD-Lys5-KLHs, wherein Bzl is benzyl, TFD is disaccharide Galβ3GalNAcα; Lys5 is a penta-lysine and KLHs is succinilated Keyhole limpets hemocyanin.

### Claim 34 (depends on 25)

The composition of claim 25, characterized by being in the form selected from the group consisting in liquid, solid, gel, and aerosol forms.

### Claim 35 (depends on 25)

The composition of claim 25, characterized by also comprising an adjuvant.

### Claim 36 (depends on 1)

The use of the immunogen of claim 1 to prepare a medication to improve anti-tumor immunity.

### Claim 37 (depends on 1)

The use of the immunogen of claim 1 to prepare a medication for the treatment of cancer.

### Claim 38 (depends on 1)

The use of the immunogen of claim 1 to prepare a medication to reduce metastatic ability of a tumor.

### Claim 39

A method for the immunization of a mammal against antigen T, characterized by this method comprising the administration of an effective amount of a composition, wherein said composition comprises a modified Thomsen-Friedenreich disaccharide (TDF) immunogen of general formula D-TFD-Lys(n)-C, wherein D is a hydrophobic terminal residue, TFD is disaccharide Galβ3GalNAcα, Lys(n) is a lysine connector, and n is an integer between 1 and 5, and C is a carrier; and pharmaceutically acceptable supports and/or excipients.

### Claim 40 (depends on 39)

The method of claim 39, characterized in that the hydrophobic terminal residue is selected from the group consisting of benzyl, p-nitrophenyl, butyl, propyl, ethyl, and methyl.

### Claim 41 (depends on 40)

The method of claim 40, characterized in that the hydrophobic terminal residue is benzyl.

### Claim 42 (depends on 39)

The method of claim 39, characterized in that the hydrophobic terminal residue is covalently linked to TFD GalNAc C1 of position a.

### Claim 43 (depends on 39)

The method of claim 39, characterized in that the lysine connector is a penta-lysine.

### Claim 44 (depends on 39)

The method of claim 39, characterized in that carrier is selected from the group consisting of Keyhole limpets hemocyanin (KLH), and muramyl-dipeptide (MDP).

### Claim 45 (depends on 44)

The method of claim 44, characterized in that the carrier is Keyhole limpets hemocyanin.

### Claim 46 (depends on 44)

The method of claim 44, characterized in that the carrier is succinilated Keyhole limpets hemocyanin.

### Claim 47 (depends on 39)

The method of claim 39, characterized in that the immunogen is BzlαTFD-Lys5-KLHs, wherein Bzl is benzyl, TFD is disaccharide Galβ3GalNAcα; Lys5 is a penta-lysine, and KLHs is succinilated Keyhole limpets hemocyanin.

### Claim 48 (depends on 39)

The method of claim 39, characterized in that the mammal is a cancer carrier.

### Claim 49 (depends on 48)

The method of claim 48, characterized in that the cancer is selected from the group consisting of breast cancer and colon cancer.

### Claim 50 (depends on 39)

The method of claim 39, characterized in that the immunogen is applied jointly with substances increasing immunity.

### Claim 51 (depends on 50)

The method of claim 50, characterized in that the substances increasing immunity are selected from the group consisting of cytokines and adjuvants.
